ORPHA:300298
Severe congenital hypochromic anemia with ringed sideroblasts
Also known as: Severe congenital hypochromic sideroblastic anemia
Publications
2,810
Trials
0
Interventional, condition-specific
Researchers
25
Distinct authors in sample
Gene link
STEAP3
Moderate
Readiness
4/6
Stages with a signal
Clinical definition (Orphanet)
A very rare severe non-syndromic hypochromic anemia characterized by transfusion-dependent hypochromic, poorly regenerative anemia and iron overload, resembling non-syndromic sideroblastic anemia except for increased erythrocyte protoporphyrin levels.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0014094
- OMIM:615234
- UMLS:C3808920
Additional Mondo synonyms (3)
anemia, hypochromic microcytic, with iron overload type 2 · severe congenital hypochromic sideroblastic anaemia · severe congenital hypochromic sideroblastic anemia
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
4/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedPresent
Moderate — STEAP3
- LiteraturePresent
2,810 matched papers (2,435 in last 10 years) Source
- Phenotype characterisedPresent
36 HPO annotations (e.g. Decreased mean corpuscular volume; Pallor; Increased circulating ferritin concentration) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 2133 for broader category anemia
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Probably — there is moderate evidence for STEAP3.
GenCC classification: Moderate.
Phenotypes (Monarch / HPO)
36
Associated phenotypes · MONDO:0014094
- Decreased mean corpuscular volume
- Pallor
- Increased circulating ferritin concentration
- Elevated hepatic iron concentration
- Splenomegaly
Showing 5 of 36 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
2,810
2,810 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
2,810 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
2,435 in the last 10 years · low confidence
Phrase hits: 2 · MeSH hits: 0
Who's working on it?
25
Distinct author names in 2 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Baños R1 paper · 2013Papers in Europe PMC
- 02Benítez J1 paper · 2013Papers in Europe PMC
- 03Bogliolo M1 paper · 2013
Genome Instability and DNA Repair Group, Department of Genetics and Microbiology, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain.
Papers in Europe PMC - 04Bueren JA1 paper · 2013Papers in Europe PMC
- 05Casado JA1 paper · 2013Papers in Europe PMC
- 06de Winter JP1 paper · 2013Papers in Europe PMC
- 07Derkunt B1 paper · 2013Papers in Europe PMC
- 08GU LIANQUAN1 paper · 2005Papers in Europe PMC
- 09HUANG SHILIANG1 paper · 2005Papers in Europe PMC
- 10HUANG ZHISHU1 paper · 2005Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 2,133 trials are registered for anemia, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
2,133 interventional trials matched anemia, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: anemia
2,133
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07657455·NOT YET RECRUITING·Daily Versus Alternate-Day Oral Iron Therapy for Anemia in Second-Trimester Pregnancy
Conditions: Iron Deficiency Anemia · Anemia in Pregnancy·Matched via name phrase
- NCT07123909·RECRUITING·Studies on Adsorption International Learning Initiative Global
Conditions: CKD (Chronic Kidney Disease) Stage 5D · Uremia; Chronic · Uremic; Toxemia · Inflammation Chronic·Matched via name phrase
- NCT07748533·RECRUITING·HY001N for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.
Conditions: Autoimmune Hemolytic Anemia (AIHA)·Matched via name phrase
- NCT07485023·NOT YET RECRUITING·Oral Versus Intravenous Iron for Anemia Diagnosed After 34 Weeks of Gestation
Conditions: Anemia Complicating Pregnancy·Matched via name phrase
- NCT07162090·NOT YET RECRUITING·Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients
Conditions: Sarcopenia · Anemia Associated With Chronic Kidney Disease (CKD) · Dialysis Patients·Matched via name phrase
- NCT06698120·NOT YET RECRUITING·Awake Prone Positioning for Severe Acute Chest Syndrome
Conditions: Acute Chest Syndrome · Sickle Cell Anemia·Matched via name phrase
- NCT01174108·RECRUITING·Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
Conditions: Severe Aplastic Anemia · MDS (Myelodysplastic Syndrome)·Matched via name phrase
- NCT05924100·RECRUITING·Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD
Conditions: Myelodysplastic Syndromes · Del(5Q) · Anemia · Transfusion-dependent Anemia·Matched via name phrase
- NCT07136792·RECRUITING·A Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI)
Conditions: Renal Anemia of Chronic Kidney Disease·Matched via name phrase
- NCT06725810·RECRUITING·Correction of Anemia With Enarodustat in Non-dialysis Dependent Chronic Kidney Disease
Conditions: Chronic Kidney Disease Associated Anemia·Matched via name phrase
- NCT07750574·NOT YET RECRUITING·Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis
Conditions: Myelofibrosis · Myelofibrosis Due to and Following Polycythemia Vera · Myelofibrosis Transformation in Essential Thrombocythemia · Myelofibrosis With High Molecular Risk Mutations·Matched via name phrase
- NCT06957717·NOT YET RECRUITING·Effect of Cow's Milk Kefir on Short Chain Fatty Acid (SCFA), Haemoglobin, and Ferritin Levels of Anemic Adolescent Girls
Conditions: Iron Deficiency Anemia·Matched via name phrase
- NCT06261398·RECRUITING·Better Birth Outcomes Through Technology, Education, and Reporting
Conditions: Pregnancy · Maternal Anemia · Pre-Term Birth · Hypertensive Disorders·Matched via name phrase
- NCT05031897·RECRUITING·Two Step Haplo With Radiation Conditioning
Conditions: Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Adult T-Cell Leukemia/Lymphoma · Aplastic Anemia·Matched via name phrase
- NCT07493772·NOT YET RECRUITING·Multiple Micronutrient Supplementation With Digital Layering Among Adolescents in Tanzania
Conditions: Anemia·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 60 · after dedupe 60 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 60 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (60)
- ctis·2025-523555-66-00·Authorised·A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients with Myelofibrosis who are JAK inhibitor naive
skipped — LLM skipped (--skip-llm)
- ctis·2025-523544-12-00·Authorised, ongoing·A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions
skipped — LLM skipped (--skip-llm)
- ctis·2025-522246-43-00·Authorised·Study in healthy male participants to compare the blood levels after epoetin alfa (Blau EPO) and Erypo, administered as multiple intravenous injections as well as safety, tolerability and the effects on certain blood values.
skipped — LLM skipped (--skip-llm)
- ctis·2025-522244-40-00·Authorised·Study in healthy volunteers to compare the blood levels after epoetin alfa (Blau EPO) and Erypo, administered as a single intravenous injection as well as safety, tolerability and the effects on certain blood values.
skipped — LLM skipped (--skip-llm)
- ctis·2025-523845-90-00·Authorised, recruiting·Safety and Preliminary Efficacy of CTX112 in Adult Participants with Relapsed/Refractory Hematologic Autoimmune Disease
skipped — LLM skipped (--skip-llm)
- ctis·2025-521286-27-00·Authorised, ongoing·INCA000585-201 - A PHASE 2A, OPEN-LABEL, MULTI-CENTER STUDY OF TAFASITAMAB IN ADULT PARTICIPANTS WITH AUTOIMMUNE BLOOD CELL DISORDERS
skipped — LLM skipped (--skip-llm)
- ctis·2025-523475-33-00·Authorised, ongoing·Caffeine Administration for Preterms: Pharmacokinetics, Utilization and Correlation Inhibiting Nociception Outcome
skipped — LLM skipped (--skip-llm)
- ctis·2024-519881-32-00·Authorised·A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients with Sickle Cell Disease
skipped — LLM skipped (--skip-llm)
- ctis·2025-522509-39-00·Authorised, ongoing·Pacritinib For The Reduction Of Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia; A Multicenter, Open-Label, Single Arm, Phase II Exploratory Study
skipped — LLM skipped (--skip-llm)
- ctis·2025-521257-17-00·Authorised, ongoing·DREPAMIR - A Phase 1/2 Open Label Cohort Comparative Study Evaluating the Efficacy and the safety of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ enriched cell fraction that contains autologous CD34+ cells transduced ex vivo by the bifunctional βAS3m/miR7m lentiviral vector expressing the βAS3m and a micro-RNA (miRNA) targeting specifically the endogenous βS-globin mRNA in Patients with Sickle Cell Disease (SCD)
skipped — LLM skipped (--skip-llm)
- ctis·2024-518231-11-00·Cancelled·Exploratory Study of Ianalumab in Adults with Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) who Have
Previously Benefited from Ianalumab (VAY RE-HIT)
skipped — LLM skipped (--skip-llm)
- ctis·2024-517753-27-01·Authorised·A multicenter, randomized clinical trial comparing the efficacy and safety of certolizumab pegol and belimumab in patients with moderate or severe activity of systemic lupus erythematosus (CERT-SLE)
skipped — LLM skipped (--skip-llm)
- ctis·2024-519779-24-00·Authorised, ongoing·GFM-VEXAS-MMB: A single-arm phase II with safety run-in multicenter study of momelotinib in patients with VEXAS syndrome with or without associated myelodysplastic syndrome
skipped — LLM skipped (--skip-llm)
- ctis·2025-520473-40-00·Authorised, ongoing·A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO).
skipped — LLM skipped (--skip-llm)
- ctis·2025-521838-29-00·Authorised, ongoing·Study of IADADEMSTAT for the Treatment of Sickle Cell Disease.
skipped — LLM skipped (--skip-llm)
- ctis·2025-521701-41-00·Authorised, ongoing·Darbepoetin in patients candidates for liver transplant: randomized clinical trial (EPO_LT trial)
skipped — LLM skipped (--skip-llm)
- ctis·2024-519928-24-00·Authorised, ongoing·A Phase 2, Randomized, Open-label, Study of Momelotinib in Participants with Anemia due to Low-risk Myelodysplastic Syndrome.
skipped — LLM skipped (--skip-llm)
- ctis·2024-519746-70-01·Expired·A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter, Dose-Finding, Efficacy, and Safety Study of Tebapivat in Participants With Sickle Cell Disease
skipped — LLM skipped (--skip-llm)
- ctis·2024-517972-39-00·Authorised, ongoing·A phase 3, multicenter, randomized, double-blind, placebo- controlled, parallel-group study with an open-label period and long-term extension to assess the efficacy and safety of rilzabrutinib in participants with warm autoimmune hemolytic anemia (wAIHA)
skipped — LLM skipped (--skip-llm)
- ctis·2024-518886-89-00·Expired·Phase II randomized study on efficacy of nintedanib for treatment of epistaxis in hereditary haemorrhagic telangiectasia (HHT) patients - EPISTOP
skipped — LLM skipped (--skip-llm)
- ctis·2024-513440-29-00·Cancelled·A Phase 2 / Phase 3, Multicenter, Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled Adaptive Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents with Sickle Cell Disease during Vaso-Occlusive Crisis
skipped — LLM skipped (--skip-llm)
- ctis·2024-516009-22-00·Authorised, ongoing·A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW)
skipped — LLM skipped (--skip-llm)
- ctis·2023-509175-16-00·Authorised, ongoing·A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease
skipped — LLM skipped (--skip-llm)
- ctis·2024-519207-10-00·Authorised, ongoing·Ravulizumab dose optimization
skipped — LLM skipped (--skip-llm)
- ctis·2024-520121-36-00·Expired·STEP-WISE COMBINATION OF OBINUTUZUMAB, VEMURAFENIB AND COBIMETINIB IN PATIENTS WITH HAIRY CELL LEUKEMIA (HCL) PREVIOUSLY TREATED WITH PURINE ANALOGS OR UNFIT FOR CHEMOTHERAPY: A PHASE-2, SINGLE-ARMS, ITALIAN, MULTICENTER STUDY (HCL-PG04)
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Severe congenital hypochromic anemia with ringed sideroblasts — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Severe congenital hypochromic anemia with ringed sideroblasts" OR "Severe congenital hypochromic sideroblastic anemia" OR "anemia, hypochromic microcytic, with iron overload type 2" OR "severe congenital hypochromic sideroblastic anaemia") OR ("STEAP3" OR "STEAP3 syndrome" OR "STEAP3-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Severe congenital hypochromic anemia with ringed sideroblasts" OR "Severe congenital hypochromic sideroblastic anemia" OR "anemia, hypochromic microcytic, with iron overload type 2" OR "severe congenital hypochromic sideroblastic anaemia"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"anemia"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (2810) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-27T12:38:48.558Z
